Oslo University Hospital

Running trials

• Not yet recruiting

  Reconsidering Long-Term Apirin in the Elderly in Secondary Prevention of Coronary Artery Disease Norway

  NCT07854795· Phase 4· Vestre Viken Hospital Trust· Source

• Not yet recruiting

  Reduced-Dose Versus Full-Dose Alteplase for High-Risk Pulmonary Embolism

  NCT07816978· Phase 4· Sahlgrenska University Hospital· Source

• Not yet recruiting

  Study Aiming to Test Whether Non-invasive Liquid Biopsies Can Safely Reduce Invasive Surveillance Methods in Lynch Syndrome

  NCT07360834· UNICANCER· Source

• Not yet recruiting

  Validation Of anatomY-specific Aortic Valve Implantation Guided by Software Using EncantoR

  NCT07696182· Abbott Medical Devices· Source

• Recruiting

  Proton Re-irradiation in Patients With Recurrent or Second Primary Head and Neck Cancer , a Multicentre Phase II Single Arm Trial

  NCT07922967· Oslo University Hospital· Source

• Not yet recruiting

  A trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.

  2026-525367-40-00· Phase 3· AstraZeneca AB· Source

• Not yet recruiting

  Phase 3 Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC 6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

  2025-524969-24-00· Phase 3· Revolution Medicines Inc.· Source

• Not yet recruiting

  Immunoprofiling of the Patient Tumor Microenvironment in BCMA Targeted Therapies

  NCT07878208· Odense University Hospital· Source

• Recruiting

  Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia

  NCT07473843· Phase 3· Arrowhead Pharmaceuticals· Source

• Not yet recruiting

  Infarct Growth After Intravenous Tocilizumab in Adults With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy - ILLUMINATE

  NCT07870681· Phase 2/3· Oslo University Hospital· Source

• Not yet recruiting

  bNAbs and Anti-PD-1 in HIV

  NCT07820813· Phase 2· Ole Schmeltz Søgaard· Source

• Recruiting

  Elastography-based Brief Alcohol Intervention in Hospitalized Individuals

  NCT07637539· Oslo University Hospital· Source

• Recruiting

  A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

  2025-525009-18-00· Phase 3· Incyte Corp.· Source

• Recruiting

  A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma.

  2025-523285-25-00· Phase 3· AstraZeneca AB· Source

• Recruiting

  Novel Technologies to Improve Echocardiographic Estimates of Left Ventricular Filling Pressure in Heart Failure Combined With Atrial Fibrillation

  NCT07436299· Oslo University Hospital· Source

• Not yet recruiting

  Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma.

  NCT07757412· Phase 2· Odense University Hospital· Source

• Enrolling by invitation

  Donor Derived Cell Free DNA (Dd-cfDNA) as a Biomarker for Allograft Rejection in Heart Transplant Recipients

  NCT07886489· University of Aarhus· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

  2025-524711-36-00· Phase 3· Alkermes Inc.· Source

• Recruiting

  A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

  NCT07753993· Phase 3· AstraZeneca· Source

• Not yet recruiting

  A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL)

  2025-524439-38-00· Phase 2· Oslo Universitetssykehus HF· Source

• Not yet recruiting

  Reassessment of statin-associated muscle symptoms in adults with familial hypercholesterolemia

  2025-521589-83-00· Phase 4· Oslo University Hospital HF· Source

• Recruiting

  Implementing the 6th Generation Cardiac Troponin T

  NCT07936630· Rasmus Bo Hasselbalch· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

  2025-523911-13-00· Phase 3· Alkermes Inc.· Source

• Recruiting

  A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

  NCT07492680· Phase 2· Bristol-Myers Squibb· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Boehringer Ingelheim· Source

• Enrolling by invitation

  Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH

  NCT07102511· Phase 3· LIB Therapeutics LLC· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.

  NCT07672236· Phase 3· OncoZenge AB· Source

• Not yet recruiting

  Does a higher radiation dose prolong survival of patients with limited-stage small cell lung cancer receiving immunotherapy after chemotherapy and radiation therapy (DAHRTS trial)?

  2026-525513-31-00· Phase 3· Norges Teknisk-Naturvitenskapelige Universitet NTNU· Source

• Recruiting

  A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer

  2025-522818-23-00· Phase 3· Zai Lab (US) LLC· Source

• Recruiting

  Prospective Natural History Study of POLG Disease

  NCT07775872· The POLG Foundation· Source

• Recruiting

  A study to investigate how a single dose of the drug melflufen reaches brain tumor tissue, and how it affects the tumour, in patients who are already scheduled for surgery for a returning glioblastoma

  2026-525543-32-00· Phase 1· Oncopeptides AB· Source

• Recruiting

  A Multiple Baseline Feasibility Trial of Social Management Training for People With Sex Chromosome Aneuploidies

  NCT07718997· Phase 1· University of Oslo· Source

• Recruiting

  A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

  NCT07393282· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions

  NCT07422480· Phase 3· Takeda· Source

• Recruiting

  MRI-Based Lesion Differentiation in Older Patients With Multiple Sclerosis

  NCT07444047· Oslo University Hospital· Source

• Recruiting

  Proton Versus Photon Therapy in Head and Neck Squamous Cell Carcinomas.

  NCT07580300· Phase 3· Oslo University Hospital· Source

• Recruiting

  Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging

  NCT07602010· Oslo University Hospital· Source

• Recruiting

  A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis

  2025-521546-23-00· Phase 3· Novartis Pharma AG· Source

• Not yet recruiting

  A randomized placebo-controlled double-blind trial phase II two-arm study to investigate infarct growth over 72 hours assessed with diffusion weighted imaging on MRI after treatment with intravenous tocilizumab or placebo in patients above 18 years of age with acute ischemic stroke undergoing endovascular thrombectomy.

  2025-521269-28-00· Phase 2· Oslo University Hospital HF· Source

• Recruiting

  DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

  NCT07472517· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer ( RAINFOL-03 )

  2024-519818-31-01· Phase 3· Genmab A/S· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

  NCT07225270· Phase 3· Genmab· Source

• Recruiting

  Optimizing Patient Treatment With EPA-enriched Nutrition, a Randomised Control Trial

  NCT07255066· University of Edinburgh· Source

• Recruiting

  Selenium Intervention Registry Randomized Trial in Heart Failure

  NCT07543562· Phase 3· Skane University Hospital· Source

• Recruiting

  Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy

  NCT07144319· Photocure· Source

• Recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

  NCT07326709· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07491445· Phase 3· Revolution Medicines, Inc.· Source

• Recruiting

  A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

  NCT07438496· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

  NCT07284849· Phase 3· Incyte Corporation· Source

Showing 50 of 235.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple myeloma11 recruiting
• Pancreatic cancer10 recruiting
• Lung cancer9 recruiting
• Childhood cancers8 recruiting
• Colorectal cancer8 recruiting
• Heart failure8 recruiting
• Liver and biliary tract cancer8 recruiting
• Prostate cancer7 recruiting
• Head and neck cancer5 recruiting
• Melanoma5 recruiting
• Bladder cancer4 recruiting
• Coronary artery disease4 recruiting
• Endometrial cancer4 recruiting
• High blood pressure4 recruiting
• Migraine4 recruiting
• Ovarian cancer4 recruiting
• Stroke4 recruiting
• Atrial fibrillation3 recruiting
• Bipolar disorder3 recruiting
• Familial hypercholesterolaemia3 recruiting
• Gastric and oesophageal cancer3 recruiting
• Myelodysplastic syndromes3 recruiting
• Sarcoma3 recruiting
• Systemic sclerosis (scleroderma)3 recruiting
• Acute myeloid leukaemia2 recruiting
• ALS (motor neurone disease)2 recruiting
• Amyloidosis2 recruiting
• Autism2 recruiting
• Cervical cancer2 recruiting
• Crohn's disease2 recruiting
• Deep vein thrombosis and pulmonary embolism2 recruiting
• Glioblastoma2 recruiting
• Huntington's disease2 recruiting
• Metastatic breast cancer2 recruiting
• Multiple sclerosis2 recruiting
• Multiple system atrophy2 recruiting
• Narcolepsy2 recruiting
• Neuroendocrine tumours2 recruiting
• Post-traumatic stress disorder (PTSD)2 recruiting
• Schizophrenia2 recruiting
• Thyroid cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Alcohol use disorder1 recruiting
• Anorexia nervosa1 recruiting
• Aortic stenosis1 recruiting
• Borderline personality disorder1 recruiting
• Charcot-Marie-Tooth disease1 recruiting
• Chronic kidney disease1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Coeliac disease1 recruiting
• Cystic fibrosis1 recruiting
• Depression1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Epilepsy1 recruiting
• Follicular lymphoma1 recruiting
• Gestational diabetes1 recruiting
• Glaucoma1 recruiting
• Haemophilia1 recruiting
• HIV1 recruiting
• Hypothyroidism1 recruiting
• Lupus (SLE)1 recruiting
• Mitochondrial disease1 recruiting
• Myocarditis1 recruiting
• Myotonic dystrophy1 recruiting
• Obesity1 recruiting
• Obsessive-compulsive disorder1 recruiting
• Osteoarthritis1 recruiting
• Osteonecrosis (avascular necrosis)1 recruiting
• Parkinson disease1 recruiting
• Peripheral artery disease1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Retinitis pigmentosa1 recruiting
• Rheumatoid arthritis1 recruiting
• Spinal cord injury1 recruiting
• Testicular cancer1 recruiting
• Turner syndrome1 recruiting
• Type 1 diabetes1 recruiting
• Type 2 diabetes1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Recruiting

  A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec

  NCT07444450· Phase 3· Biogen· Source

• Completed

  Exercise as Treatment for Patients With Inclusion Body Myositis

  NCT06644482· Oslo University Hospital· Source

• Completed

  Clinical Validation of Immunovia Next-Generation Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer

  NCT06947382· Immunovia, Inc.· Source

• Withdrawn

  The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)

  NCT06291415· Phase 1· Hutchmed· Source

• Active, not recruiting

  Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

  NCT06151574· Phase 3· Boehringer Ingelheim· Source

• Terminated

  Clinical Utility of Selected Circulating Tumor DNA Assays in Patients With Advanced Malignancy

  NCT06290856· Oslo University Hospital· Source

• Completed

  Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)

  NCT06122961· Novo Nordisk A/S· Source

• Completed

  Self-management Program for Patients in the Sub-acute Phase After Traumatic Injury - a Feasibility Study

  NCT06093074· Oslo University Hospital· Source

• Terminated

  Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies

  NCT05609942· Phase 1· Blueprint Medicines Corporation· Source

• Completed

  Nevoid Basal Cell Carcinomas in Gorlin Syndrome

  NCT05898347· Oslo University Hospital· Source

• Completed

  Ultrasound for Detection of Prostate Cancer

  NCT05736094· Oslo University Hospital· Source

• Completed

  A Study of TAK-861 in Participants With Narcolepsy Type 2

  NCT05687916· Phase 2· Takeda· Source

• Terminated

  Home Blood Pressure Monitoring in Kidney Transplant Recipients

  NCT04364126· Oslo University Hospital· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Boehringer Ingelheim· Source

• Terminated

  Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia

  NCT05079230· Phase 3· Gilead Sciences· Source

• Completed

  Blood Flow Restriction Exercise in Patients With Pancreatic, Biliary Tract, and Liver Cancer (PREV-Ex)

  NCT05044065· Karolinska Institutet· Source

• Completed

  A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma

  NCT05243342· Phase 1· Genentech, Inc.· Source

• Completed

  Intensiv Inpatient Trauma Treatment. A Pilotstudy.

  NCT05342480· Oslo University Hospital· Source

• Completed

  Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT05218499· Phase 2/3· Boehringer Ingelheim· Source

• Completed

  New-onset Severe Headache After Covid-19 Vaccine

  NCT05235776· Oslo University Hospital· Source

• Completed

  Zoledronate Early to Hip Fracture Patients - Safe and Effective?

  NCT05025293· Phase 4· Lene Bergendal Solberg· Source

• Completed

  A Complex Intervention for Chronically Fatigued Lymphoma Survivors

  NCT05130099· Oslo University Hospital· Source

• Completed

  The Oslo Study of Visual Impairment After Stroke (StrokeVIS)

  NCT05809973· Oslo University Hospital· Source

• Completed

  A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

  NCT05076149· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  NETwork of Linoleic Acid Supplementation in Cystic Fibrosis

  NCT04531410· Karolinska Institutet· Source

• Completed

  Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (Z-AMD)

  NCT04304755· Phase 2· Oslo University Hospital· Source

• Completed

  Stability of Uncemented Medially Stabilized TKA

  NCT04017533· Oslo University Hospital· Source

• Completed

  A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial

  NCT04876391· Phase 2· Boehringer Ingelheim· Source

• Terminated

  HAI-Floxuridine, or Liver-Tx, Combined With 2nd Line Chemotherapy Versus 2nd Line Chemotherapy Alone for Patients With Colorectal Liver Metastases and Heavy Tumour Burden.

  NCT04898504· Phase 2· Oslo University Hospital· Source

• Terminated

  Open-Label Surufatinib in European Patients With NET

  NCT04579679· Phase 2· Hutchmed· Source

• Terminated

  A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

  NCT04740918· Phase 3· Hoffmann-La Roche· Source

• Completed

  Prosthesis Versus Active Exercise Program in Patients With Glenohumeral Osteoarthritis

  NCT04845074· University of Aarhus· Source

• Terminated

  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

  NCT04272034· Phase 1· Incyte Corporation· Source

• Terminated

  Study to Evaluate Safety and Efficacy of IBsolvMIR in Islet Transplantation

  NCT03867851· Phase 2· TikoMed AB· Source

• Terminated

  A Phase I/II Study With BM7PE Immunotoxin in Colorectal Cancer Patients

  NCT04550897· Phase 1/2· Oslo University Hospital· Source

• Completed

  Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer

  NCT04405349· Phase 2· Nykode Therapeutics ASA· Source

• Completed

  Altered Tumor Oxygenation by Metformin, a Potential Step in Overcoming Radiotherapy Resistance in LACC

  NCT04275713· Phase 2· Oslo University Hospital· Source

• Completed

  A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease

  NCT03568968· Phase 3· Haukeland University Hospital· Source

• Completed

  Boosting Biologics in UC

  NCT04241029· Oslo University Hospital· Source

• Completed

  Radiotherapy of Head and Neck Cancer Using an Intraoral Stent

  NCT04330781· Phase 2· Oslo University Hospital· Source

• Completed

  Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)

  NCT04934800· Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany· Source

• Completed

  The Lifestyle and Empowerment Techniques in Survivorship of Gynecologic Oncology Study

  NCT04122235· Sorlandet Hospital HF· Source

• Completed

  Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS)

  NCT04121403· Phase 3· Oslo University Hospital· Source

• Completed

  CIRSE Emprint Microwave Ablation Registry

  NCT03775980· Cardiovascular and Interventional Radiological Society of Europe· Source

• Completed

  Danish RAndomized Trial of External Ventricular Drainage Cessation IN Aneurysmal Subarachnoid Haemorrhage

  NCT03948256· Copenhagen University Hospital, Rigshospitalet· Source

• Completed

  Effect of FODMAP Restriction on Persistent GI-symptoms in Coeliac Patients

  NCT03678935· Oslo University Hospital· Source

• Completed

  Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix

  NCT03556839· Phase 3· Grupo Español de Investigación en Cáncer de Ovario· Source

• Completed

  Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

  NCT03353831· Phase 3· AGO Research GmbH· Source

• Completed

  Change in Cognition and Frailty After Shunt Surgery in Idiopathic Normal Pressure Hydrocephalus (iNPH)

  NCT07642726· Oslo University Hospital· Source

• Terminated

  Study of Antithrombotic Treatment After IntraCerebral Haemorrhage

  NCT03186729· Phase 4· Oslo University Hospital· Source

Showing 50 of 66.

Conditions

Diseases this institution publishes on or runs trials for.

• Stroke142 works · 10 trials
• Heart failure103 works · 9 trials
• Colorectal cancer71 works · 21 trials
• Schizophrenia70 works · 2 trials
• Bipolar disorder55 works · 2 trials
• Prostate cancer53 works · 10 trials
• Epilepsy44 works · 1 trial
• Systemic sclerosis (scleroderma)37 works · 4 trials
• Coeliac disease34 works · 4 trials
• Mild cognitive impairment33 works · 1 trial
• Coronary artery disease32 works · 6 trials
• Depression31 works · 1 trial
• Multiple myeloma31 works · 13 trials
• Ulcerative colitis31 works · 3 trials
• Type 1 diabetes26 works · 3 trials
• Rheumatoid arthritis25 works · 2 trials
• Sarcoma24 works · 4 trials
• Ventricular tachycardia23 works · 0 trials
• Crohn's disease23 works · 2 trials
• Insomnia22 works · 0 trials
• Glioblastoma22 works · 4 trials
• Delirium21 works · 1 trial
• ADHD20 works · 0 trials
• Anxiety disorders (generalised anxiety)19 works · 0 trials
• Idiopathic pulmonary fibrosis19 works · 1 trial
• Migraine18 works · 5 trials
• Post-traumatic stress disorder (PTSD)17 works · 4 trials
• Hodgkin lymphoma16 works · 0 trials
• Gestational diabetes14 works · 1 trial
• Endometrial cancer13 works · 6 trials